Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet for NKF K/DOQI Targets in Australian ESRD Patients on Aranesp
NCT00431496Phase 4Completed
- Sponsor
- Amgen
- Start
- Sep 2006
- Primary completion
- Jun 2009
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of cinacalcet in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Number of Participants With a Mean Intact Parathyroid Hormone Value Between 150 and 300 pg/mL and a Calcium - Phosphorus Product Value < 55 mg^2/dL^2. Started Sep 2006; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00431496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431496.